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IN  RECOVERY  FROM  FRIEND  VIRUS  LEUKEMIA 
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(From the Department of Health, Education, and Welfare, Public Health Service, National 
Institutes of Health, National Institute of Allergy and Infectious Diseases, Rocky Mountain 
Laboratory,  Hamilton, Montana 59840 ) 
Cell-mediated immune phenomena appear to play a major role in host defense 
against antigenically foreign cells such as allografts and tumors. Passive trans- 
fer of immune  lymphoid cells can often accelerate allograft  rejection (1,  2) or 
protect specifically against challenge with neoplastic cells (3, 4). In the case of 
mouse leukemia  and  sarcoma virus-induced  tumors several different cell-me- 
diated immune mechanisms have been demonstrated in vitro (see references 5-7 
for review). However, the in vivo roles and relative importance of these mecha- 
nisms remain unclear at this time. 
Friend virus (FV)  ~ mouse leukemia presents an excellent model for investiga- 
tion of host defenses involved in recovery from primary virus-induced neoplasia. 
The onset of disease is very rapid and immunologically mature adult mice of 
many strains are susceptible to induction of the leukemia. Furthermore, several 
genes have been identified  that  influence  FV leukemia including  one (Rfv-1) 
which appears to affect recovery from established leukemia (8-11). The possible 
role of the host immune response in the mechanism of action of this and other H- 
2-associated genes  influencing  mouse leukemia has  been postulated  (9).  The 
previous paper in this series presented data on the humoral immune response to 
FV and FV-induced leukemia cells (12). This paper will examine some aspects of 
the specific cell-mediated immune response in this disease. The results indicate 
that  0-positive cells,  which are specifically cytotoxic for FV leukemia cells in 
vitro, appear in the spleens of mice during or after spontaneous recovery from 
FV-induced splenomegaly. Mice of both high and low recovery (Rfv-1) genotypes 
can  produce  these  effector cells,  and  thus  the Rfv-1  gene  does  not  seem to 
function  by  means  of an  absolute  control  over  production  of these  specific 
immune cells. The virus-induced antigens detected by the cytotoxic cells in this 
system appear to be different than those detected with serological techniques. 
Furthermore,  the  H-2  type  of the  leukemia  cells  seems  to  play  a  role  in 
expression of these antigens. 
1  Abbreviations used  in  this paper:  ADNCC,  antibody-dependent  normal  lymphoid cell-me- 
diated cytotoxity; B/T-L, BALB Tennant leukemia virus; CMC, cell-mediated cytotoxicity; FFU, 
focus-forming units;  FV,  Friend leukemia virus; LCM,  lymphocytic choriomeningitis; MoILV, 
Moloney leukemia virus; MSV, Moloney sarcoma virus; RLV, Rauscher leukemia virus. 
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Materials and Methods 
Mouse strains, buffers, virus preparations,  virus assay, and spleen palpation techniques were 
described previously (11,  12). In addition,  B10.A(18R) mice were provided by Dr. J. Stimpfling, 
Great Falls, Montana. These mice have the b allele of the H-2K region and the d allele of the H-2D 
region.' The F, produced by mating these mice with A.BY mice has the Rfv-1 ~  genotype with a 
pattern of recovery from FV-induced splenomegaly identical to (B10.A  x  A.BY)FI mice. 
Lyrnphoma  Cell Lines.  A13,  BB4,  BC1,  BC2,  and  BC-3A tumor lines were induced by i.p. 
inoculation of 1-6-day-old mice with  BALB Tennant  leukemia  (B/T-L) virus.  B/T-L virus was 
selected because it is the helper MuLV for the B-tropic FV stock used (13), and thus these viruses 
have common envelope antigens. A13 and BB4 were from BALB.B (H-2~b)mice, and BC1, BC2, and 
BC-3A were from BALB/c (//-2  dl~) mice. Mice developed leukemia 2-5 mo after virus inoculation, 
and lymph node cell suspensions were passed i.p. to syngeneic mice. Usually the cells grew in the 
spleen and lymph nodes; however, after repeated i.p. passages, cells grew freely throughout the 
peritoneal cavity and were maintained as ascites lines. T2, T4, TS, and HFL/d-sc tumor lines were 
derived from  BALB/c mouse  spleens  50-70  days  after  inoculation  with  NB-tropic  FV.  Spleen 
fragments  (1-3 mm) were injected subcutaneously  in BALB/c recipients.  Subcutaneous  tumors 
grew in 10-20 days, and cells were passed i.p. as ascites cells thereafter. HFL/d-sc was produced in 
the laboratory of Dr.  F.  Lilly, Albert Einstein School of Medicine, Bronx,  New York and was 
provided to us in the 49th subcutaneous passage (14, 15). FBL-3 is a C57BL/6 lymphoma induced by 
the lymphatic leukemia helper virus of the FV complex. It was provided by Dr. A. Fefer of the 
University of Washington  School of Medicine,  Seattle,  Wash.  LSTRA is a  BALB/¢ lymphoma 
induced by Moloney leukemia  virus and was provided by Dr. J.  Wunderlich,  National Cancer 
Institute, Bethesda, Md. RBL.5 and EIA(G-) are both C57BL/6 lymphomas and were provided by 
Dr. R. Herberman, National Cancer Institute,  Bethesda,  Md. 
Ascites cells were also grown in vitro as stationary suspension cultures in RPMI 164{} with 10% 
fetal calf serum, 200 U/ml penicillin, and 10 ~M 2-mercaptoethanol.  Cells were inoculated at an 
initial  density  of  5-10 x 104  cells/ml  and usually grew to  a maximum  concentrations of  2-4 x 106/ml 
within 3-5 days, at which time cells  were passed by direct  transfer  of  the appropriate number of 
cells  into  a new flask  with fresh medium. 
58  is  an FV-induced cell  line  from the leukemic spleen ofa (B10.A(4R) × A.BY)FI mouse. Spleen 
cells were grown directly  in vitro in stationary suspension  cultures and passed thereafter as 
described above. These cells  have only been propagated in vitro,  and numerous attempts to grow 
them in vivo have been unsuccessful. 
Cell-Mediated Cytotoxicity  (CMC).  A  microadaptation  of the assay of Brunner et al. was 
employed (16).  Immune and normal *'attacker"  spleen cells  were dissociated  in 12 ml phosphate- 
buffered  balanced salt  solution  (PBBS), and large  clumps were removed by  decanting. Suspensions 
were centrifuged 1,500  rpm for 5 rain,  cell  pellets  were resuspended in RPMI  1640 medium, as 
described above, and the  number of  viable  nucleated cells  was determined. The concentration was 
adjusted to 13.3  x 10~/ml  and 0.15  ml (2 × 10  ~  cells)  was pipetted  into  quadruplicate wells  of  Linbro 
sterile  fiat  bottomed microtiter trays (Linbro Chemical Co., New Haven, Conn.). Target lym- 
phoma cells  were labeled with sICr  as described (12),  washed three times, and resuspended in 
medium at  a concentration of  4 x 10  ~  cells/ml.  0.025  ml (1 x 104  cells)  was delivered into  each well 
with a dropper, and trays were then incubated for 19-20 h in 5% COs in air at 34°C.  3 After 
incubation the trays  were centrifuged 1,000  rpm for  5 rain,  and 0.100  ml of  supernate was removed 
from each well and counted in an automatic gamma  counter. Control wells contained normal 
spleen cells,  and percent cytotoxicity  was calculated as: 
cpm immune spleen - cpm normal spleen x 100 
total  cpm targets - cpm normal spleen 
When inhibition  assays (17)  were performed, attacker spleen cells  were used at a concentration 
of  20 x 106/mI,  and 0.100  ml (2 x 106  cells)  was added to  each well.  Inhibitor  cells  or sera  were used 
2  Stimpfling, J. 1975.  Personal communication. 
3  Although the CMC  also  worked at 37°C, 34°C was found empirically to give optimal specific 
cytotoxicity  due to a reduction in nonspecific  sICr  release  and no significant  decrease in immune 
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at various concentrations and were added to wells in a  volume of 0.050  ml.  Targets were then 
added by dropper as before. Assay of  antibody-dependent  normal lymphoid cell-mediated  cytotoxic- 
ity (ADNCC) (18) was done in a similar fashion to the inhibition CMC assay. In some experiments 
15,000  focus-forming units (FFU) of B-tropic FV (C57BL/10  x  A.BY)F1  stock) was added to the 
wells to chock for possible inhibition of CMC. 
Irradiation.  Attacker cells were given 2,000 R at 31 rads/min using a GE Maximar X-ray unit 
at 250 kV, 15 mA, with 1-mm Cu and 1-mm A1 filters. 
Antisera.  Anti-8 serum was prepared as described by Reif and Allen (19). Serum was absorbed 
with 0-negative BALB/c lymphoma cells before use. When tested for cytotoxicity using absorbed 
rabbit serum as complement (C'), absorbed anti-0 serum killed 0-positive mouse lymphoma cells 
(EL4, A13, BB4), and did not kill known 0-negative mouse lymphoma cells (FBL-3, LSTRA, BC1). 
When tested against normal (C57BL/10  x  A.BY)F1  spleen cells 40-50% cytotoxicity was observed. 
Anti-Ia8 serum was prepared in (B10.A  ×  A/WySn)FI mice by immunizing With B10.D2  tail 
skin grafts followed by booster injections of spleen cells (20-40 x  10  s cells i.p.) at 14-day intervals. 
Mice were bled after 3-6 injections. Similar to results reported with B10.A anti-B10. D2 serum (20), 
our anti-Ia8 serum in the presence of rabbit C' killed 40-50% of normal C57BL/10  or (C57BL/10  × 
A.BY)F~  spleen cells,  >95%  of several Ia8-positive lymphomas and 0% of an Ia8-negative lym- 
phoma (EL4). (Lymphomas were typed for presence of Ia8 using direct cytetoxicity with anti-Ia8 
sera kindly provided by Dr. D. Sachs, National Cancer Institute, Bethesda, Md.) 
(C57BL/10  x  A.BY)F1  and (B10.A  x  A.BY)F~  anti-FV serums were from mice inoculated i.v. 
with 15,000 FFU B-tropic FV stock from syngeneic mice. Mice that recovered from splenomegaly 
were bled 30-50 days later. 
H-2* anti-H-2  b serum was obtained by immunizing (B10.D2  x  BALB/c)F~  mice with C57BL/10 
tail skin grafts followed by i.p. booster inoculation of spleen cells at 14-day intervals. Mice were 
bled 10 days after the fourth inoculation. 
Anti-O and Anti-Ia8 Treatment of  Spleen Cells.  Diluent was PBBS with 5% fetal calf serum. 40 
x  106 attacker spleen cells were incubated with 0.125 ml anti-0 serum or 0.2 ml anti-Ia8 serum or 
similar amounts of normal mouse serum in a total volume of 2 ml for 30 min at 37°C. Cells were 
then washed twice, resuspended in a  1.0-ml volume, and 1 ml of a one:eight dilution of absorbed 
rabbit serum (12) was added as C' source. Cells were incubated 45 min at 37°C, washed twice, and 
viable nucleated cells counted. Cells were then tested as usual in the CMC assay. 
Removal of Adherent Cells from Spleen Populations.  Glass-adherent cells were removed from 
attacker spleen suspensions using columns of glass beads (Superbrite, type 100-5005, Minnesota 
Mining and Manufacturing Co., St. Paul, Minn.). 200 x  10  e cells were absorbed for 20 min at 37°C 
on a  15-ml  column of beads in PBBS with 5% fetal calf serum, and unattached cells were then 
eluted, washed, and used in the CMC assay. Recovery was usually 10-25% of the original cell 
population.  In two experiments (no.  1 and  2,  Table  V)  glass-adherent cells were removed by 
incubation of 40 x  10  ~ attacker spleen cells in 20-ml medium at 37°C in 1 liter prescription bottles 
(110 cm  2 absorption surface). Unattached cells (30% of  original cell population) were decanted after 
90 rain and used in the CMC assay. No phagocytosis of latex particles was seen in the nonadherent 
cell populations obtained by either of these methods. 
Results 
Correlation of CMC with Regression of FV-Induced Splenomegaly.  Spleen 
cells from mice of various strains previously inoculated with FV were tested as 
attackers in the CMC assay using A13 target cells.  Spleen cells from both high 
recovery,  Rfv-1 bib,  mice  [(C57BL/10  x  A.BY)F~,  (B10.A(1R)  x  A.BY)F~, 
(B10.A(2R)  x  A.BY)F~,  (B10.A(4R)  ×  A.BY)F1  and  (C57BL/10  x  BALB.B)F~] 
and low recovery, Rfv-1 alb, mice [(B10.A  x  A.BY)F~, (B10.A(5R)  x  A.BY)F~ and 
(B10.A(18R)  x  A.BY)F~] were observed to produce significant cytotoxicity (Ta- 
ble I). With all genotypes, there was a very strong correlation between recovery 
from splenomegaly (regressor mice) and significant CMC. Of mice with spleno- 
megaly (progressor mice),  only 2 of 26 were positive in the CMC assay. Both of 
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TABLE  I 
Correlation  of CMC with Regression of FV-Induced Splenomegaly 
Rfv-1  genotype 
CMC II  b/b*  d/b$  b/b§ 
>5%  ---5%  >5%  -<5%  >5%  -<5% 
Regressor mice¶  61  10  19  3  7  1 
Progressor mice  0  8  2  9  0  7 
* IncludesRfv-1  bib mouse strains (C57BL/10  × A.BY)F1, (B10.A(1R)  × A.BY)FI, 
(B10.A(2R)  × A.BY)FI, and (B10.A(4R)  × A.BY)F~ given 15,000 FFU FV i.v. 
Spleens were assayed 4-34 days after virus inoculation. P  value <0.001. 
Includes Rfv-1 dlb mouse strains (B10.A  ×  A.BY)Fz, (B10.A(5R)  ×  A.BY)F~, 
and (B10.A(18R)  × A.BY)F~  given 15,000 or 1,500 FFU FV i.v. Spleens were 
assayed 10-41 days after virus inoculation. P  value <0.001. 
(C57BL/10  ×  BALB.B)FI mice (Rfv-1 ~lb) given 300 FFU FV i.v. Spleens were 
assayed 14-46 days after virus inoculation. P  value <0.001. 
Cell-mediated cytotoxicity against '~JCr-A13 target cells.  Values of greater 
than 5% specific cytotoxicity were considered positive. 
Criteria for regression of splenomegaly were described in reference 11. 
already initiated recovery mechanisms. This discrepancy probably represents 
the inaccuracy inherent in spleen palpation as a measure of disease state. The 
incidence of regression seen in Table I for low recovery genotype mice (Rfv-1 djb) 
does not represent a typical population incidence, since mice without splenomeg- 
aly were preferentially selected to demonstrate their ability to produce CMC. In 
addition, a  lower virus dose (1,500 FFU) was given to many of these mice to 
increase the incidence of recovery (11) and provide regressor spleens for the 
CMC assay. 
There  was  a  wide  range  of percent  cytotexicity observed  with  all  mouse 
strains studied. The data for individual mice of high and low recovery Rfv-1 
genotypes suggest that both genotypes can produce CMC of equal magnitude 
when tested at the optimal time during or after recovery from splenomegaly 
(Fig.  1 and 2).  Peak CMC tended to occur between 10 and 35 days after virus 
inoculation, and this coincided with the usual time of regression of splenomeg- 
aly in these strains at the virus doses studied. Later than 35-40 days postinocula- 
tion most CMC values were near or below 5%, which was generally the area of 
borderline statistical significance. There was a small number of mice (10 of 71 in 
Fig. 1 and 3 of 22 in Fig. 2) that gave 5% or lower CMC even though they were 
examined at the apparent optimum time after recovery from splenomegaly. The 
reason for this finding is unclear. These mice could have been on the verge of a 
relapse  of splenomegaly, as  sometimes occurs,  or possibly their spleens still 
contained enough neoplastic cells to compete with the 51Cr-labeled  targets in the 
in vitro assay. 
Specificity  of  the  CMC.  As  shown  above,  attacker  spleen  cells  from 
(C57BL/10  ×  BALB.B)F1 mice could lyse A13 (BALB.B) target cells effectively. 
Since BALB.B is one of the parents of these hybrid mice, there should be no 
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FIG.  1.  CMC  values obtained  using attacker spleen cells from individual Rfv-1 b'b  (high 
recovery incidence)  mice  [(C57BL/10  x  A.BY)F,  (B10.A(1R)  x  A.BY)F~,  (B10.A(2R)  x 
A. BY)F,  and (B10.A(4R) x  A.BY)F~] tested against s~Cr-labeled A13 target cells at various 
times after i.v. inoculation of FV (15,000 FFU  (C57BL/10 x  A.BY)F~ stock). Greater than 5% 
cytotoxicity was considered significant. 
target  cells.  However,  with  the  A.BY  hybrid  congenic  series  of  attackers, 
targets  and  attackers  in  the  CMC  assay  were  not  always  identical  for  cell 
membrane  transplantation  antigens,  and it was important to investigate  the 
specificity of the CMC that was observed. As noted in the methods, virus stocks 
used for inoculation were from spleens of syngeneic mouse strains and therefore 
should contain no immunizing nonviral antigens. To further examine the speci- 
ficity of the CMC observed, inhibition experiments were performed using unla- 
beled spleen cells from normal mice and mice with FV-induced splenomegaly as 
competitors against the s~Cr-labeled A13 target cells.  Spleen cells from mouse 
strains (C57BL/10 x  BALB.B)F~,  (C57BL/10  x  A.BY)Ft, (B10.A  × A.BY)F~, and 
(B10.A  ×  A/WySn)F~  were  tested  for  inhibition  of CMC  using  (C57BL/10  × 
A.BY)F~  attackers.  The results are shown in Fig.  3.  For each inhibitor strain 
tested  the  normal  spleen  cells  gave  no  inhibition  of CMC,  whereas  the  FV 
leukemic  spleen cells gave a  significant concentration-dependent  depression of 
CMC.  Identical  results were obtained using (B10.A  x  A.BY)F~  attacker cells. 
These  observations  suggest that in this  system the  lysis  obtained  is directed 90  CELL-MEDIATED  IMMUNITY  AND  RECOVERY  FROM  LEUKEMIA 
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Fro.  2.  CMC  values  obtained  using  attacker  spleen  cells  from  individual  Rfv-1 b~  (low 
recovery  incidence)  mice  [(B10.A  x  A.BY)F],  (B10.A(5R)  ×  A.BY)F~,  and (B10.A(18R)  × 
A.BY)FI] tested against 5'Cr-labeled A13 target cells at various times after i.v. inoculation 
of FV (1,500  or  15,000  FFU  (B10.A  x  A.BY)F,  stock).  Greater than  5% cytotoxicity  was 
considered significant. 
against viral-induced cell  surface antigens and not against normal spleen cell 
antigens. 
Comparison  of CMC with Antibody and C'-Mediated Cytotoxicity.  Using a 
series  of mouse leukemia  cell  lines,  we compared  the  specificity  of the CMC 
assay to the specificity of cytotoxicity mediated by antibody and C'. Antiserum 
and attacker spleen cells used were obtained from (C57BL/10 × A.BY)F1, (B10.A 
× A.BY)F1, and (B10.A × A/WySn)F1 mice 20-40 days after inoculation with FV. 
The results (Table II) indicated a striking difference in the specificity of lysis with 
these two techniques.  All leukemia virus-induced cell lines were lysed by anti- 
body and C'.  However,  with one exception (BC1),  only the leukemia  virus-in- 
duced lines possessing H-2 b specificities  were killed in the CMC assay system. 
BC1, the only 1t-2 did line to show any lysis,  was always lysed to a lesser extent 
than the I-I-2 bib lines, and in many cases was negative with attackers that gave 
strongly  positive  lysis using A13 target  cells.  Among the positive H-2 b~b lines 
there was some consistent variation in the amount of CMC observed, which sug- 
gested that some differences  in cell surface antigenicity  might be present.  For BRUCE  CHESEBRO  AND  KATHY  WEHRLY  91 
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FIG.  3.  Quantitative inhibition of CMC by normal and FV-induced 8-10 day leukemic 
spleen cells:  (C57BL/10  x  BALB.B)F1  (~-2blb);  (C57BL/10  x  A.BY)F1  (H-2btb); (B10.A  x 
A.BY)F=  (H-2atb); (B10.A  x  A/WySn)FI  (H-2a/a);  (C57BL/10  x  A.BY)F~  anti-FV attacker 
spleen cells and s~Cr-labeled A13 target cells were used. Values shown are the means +- 
standard error of the mean from three experiments. 
example, relatively poor lysis was always obtained using RBL-5. 4 
Many of the cell lines were tested with the CMC inhibition assay. A13, 58, and 
BB4  showed strong  inhibition  of the  lysis  of 51Cr A13  cells.  RBL-5  showed 
weaker inhibition, and none of the 1]-2 did lines, including BC1, showed inhibi- 
tion. These results confirm the findings of the direct CMC tests and indicate that 
even though I-1-2 did tumor cells have virus-induced surface antigens detectable 
by antibody and C', they do not possess the appropriate viral-induced antigens 
for detection by direct CMC or inhibition of CMC. 
One surprising finding in these experiments was the inability of (B10.A  x 
A/WySn)F~ (//-2 a/a) anti-FV attacker cells to lyse A13 or any of the other it-l-2 bib 
target cells lysed by congenic H-2 bib  or H-2 a/b  anti-FV  attacker cells.  1-1-2  ala 
attackers were consistently able to lyse only line 58 target cells (/'/-2blh-35~).  This 
observation could possibly be explained by a requirement for partial I-1-2  iden- 
tity between target and attacker in this virus-specific lysis, as has been reported 
in the lymphocytic choriomeningitis (LCM) virus system (21). 
Effect of Humoral  Antibody  on CMC.  It was of major interest to study the 
effect of humoral antibody on the CMC assay. Normal mouse serum, anti-H-2 b 
4 In a similar CMC assay system using C57BL spleen cells from MSV inoculated mice (29), the 
opposite situation was observed as greater lysis was seen with RBL-5 targets than with A13.  R. 
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TABLE  II 
Comparison  of Antibody Plus Complement-Mediated Cytotoxicity with CMC for a Series of 
Lymphoma Cell Lines 
Antibody 
and C'-me- 
Cell-mediated cytotoxicity§ 
diated cyto-  H-2  ~  anti-FV  H-2 ala anti-FV  H-2  ~  anti-FV 
Tumor  Strain  //-2 type  Virus*  toxicity$  attacker cells  attacker cells  attacker cells 
%C  %C  %C vs.  %C  %C vs.  %C  %C vs. 
A13  A13  58 
Inhibi- 
tion of 
CMC II 
A13  BALB.B  b/b  Bfr-L  50  56.0  --  15.2  --  -0.6  15.9  + 
BB4  BALB.B  b/d  Bfr-L  55  47.0  56.0  15.2  15.2  -3.1  15.9  + 
58  (B10.A(4R)  b/h-35g  FV  41  29.4  56.0  10.0  15.2  15.9  --  + 
x  A.BY)F~ 
RBL-5  C57BL/6  b/b  RLV  NT  33.1  56.0  10.0  15.2  -7.9  10.1  + 
FBL-3  C57BL/6  b/b  FV  40  39.6  56.0  15.7  15.2  0.2  15.9  + 
EL4  C57BL/6  b/b  --  5  -0.4  56.0  2.6  15.2  0.1  10.1  - 
BC1  BALB/c  d/d  Bfr-L  54  12.1  56.0  5.9  13.2  3.0  15,9  - 
BC2  BALB/c  d/d  Bfr-L  68  3.3  56.0  3.7  13.2  3.0  15.9  - 
BC-3A  BALB/c  d/d  Bfr-L  80  3.7  19.3  NT  --  NT  --  - 
LSTRA  BALB/c  d/d  MolLV  44  1.2  16.1  NT  --  NT  --  - 
T2  BALB/c  d/d  FV  68  3.1  39.5  0.9  12.0  0.8  10.8  - 
T4  BALB/c  eYd  FV  65  2.3  39.5  -1.1  12.0  1.6  10.8  - 
T5  BALB/c  d/d  FV  53  1.6  39.5  -0.7  12.0  -2.1  10.8  - 
HFL/d-sc  BALB/c  d/d  FV  46  1.3  39.5  -7.8  12.0  -9.4  10,8  - 
* Denotes virus believed to have induced the primary neoplasm from which each line was derived. 
S~Cr release assay with (C57BL/10 x  A.BY)FI anti-FV serum and rabbit C' was used as described (12). Cells were also 
examined in an indirect fluorescence assay using the same anti-FV serum followed by fluorescein-conjugated rabbit 
antimouse Ig serum. All tumor lines tested were positive except EIA. 
§ CMC was ammyed  using spleen cell attackers from mice that had recovered  from FV-induced splenomegaly.  1t-2 #~b anti- 
FV attacker cells were from (C57BL/10 x  A.BY)FI mice given 15,000  FFU FV i.v. ; H-2  a/b anti-FV attacker cells were 
from (B10.A ×  A.BY)F~ mice given 1,500 FFU FV i.v.; H-2 Qja anti-FV attacker cells were from (B10.A ×  A/WySn)F~ 
mice given 150 FFU FV i.v. Spleens were used 11-30 days after FV inoculation. 
JJ Inhibition ofCMC byH-2 ~  anti-FV spleen cells against A13 targets was tested using inhibitor:target ratios of:  5,  10, 
and 20. The criteria for positive inhibition were the same as described by Herberman et al. (31). 
serum, and serum from mice that had recovered from FV-induced splenomegaly 
were added to the CMC assay system. In addition to the usual normal spleen 
and anti-FV spleen attackers,  allogeneic attacker cells (H-2 d anti-H-2  b)  were 
obtained  by  immunizing with  a  non-FV  tumor  line  (EL4).  The  results  are 
presented in Table III. As has been previously reported using other target cells 
(22, 23) the anti-H-2 b serum was effective in inhibition of the anti-EIA (anti-H- 
2 b) attackers. The anti-FV sera had no such inhibitory effect on these attacker 
cells. When (C57BL/10  ×  A.BY)F1  anti-FV attacker cells were used, no inhibi- 
tion was observed (Table III). Several experiments were carried out using anti- 
FV sera, some with titers equal to that of  the anti-H-2 b serum previously used as 
a  successful inhibitor of anti-H-2 b attackers; however, in no case was specific 
inhibition of anti-FV attacker spleen cells seen. Preliminary experiments using 
FV suspensions (15,000 FFU/well) and in vitro prepared FV-antibody complexes 
also failed to inhibit CMC (data not shown). 
ADNCC was demonstrated with the anti-H-2  b serum, but not with anti-FV 
sera (Table III). The reason for this discrepancy is not known. 
Characterization  of Attacker Spleen  Cells.  To clarify the roles of different 
types of spleen cells as affectors in this CMC system, experiments with anti-0 
and anti-Ia8 were carried out. The Ia8 antigen has been found in large quantity BRUCE  CHESEBRO  AND  KATHY  WEHRLY 
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Effect of Various Sera on  Cell-Mediated Cytotoxicity  Using A13  Target Cells 
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Attacker spleen celis~ 
Serum* 
Normal  H-2 ~j~  Normal  H-2 bib  H-2 bib 
H-2 did  anti-EL4  H-2 bib  anti-FV  anti-FV 
Diluent only  4.7  +__  0.8  77.9  -+ 0.4  -1.8  -+ 0.5  24.4  _+  1.6  38.0  -+  1.3 
Normal H-2  b~b serum  0.9  _+  0.5  68.8  -+  2.6  -0.6  --_ 0.5  22.7  _  1.0  33.5  -+  1.3 
Anti-H-2  b serum  12.0  _+ 0.8§  46.2  -  1.5§  0.1  -+ 0.6  18.8  -+  1.5  NT 
H-2~b anti-FV serum  0.6  -+ 0.7  71.5  --+- 0.9  1.8  _+  1.0  1.9.7 -+ 0.5  37.1  -+  1.7 
H-2albanti-FVserum  NT  NT  NT  NT  34.3  -+ 0.8 
* Using antibody and complement-mediated cytotoxicity and A13 target cells, the anti-H-2  ~ serum 
had a titer of 512, the H-2  b/o anti-FV serum had a titer of 128, and the H-2  alb anti-FV serum had a 
titer of 512. 
* H-2 ~ld mice used were (B10.D2  ×  BALB/c)F~.  Anti-EL4 spleen cells were obtained  10-14  days 
after i.p.  injection of i  x  10  e viable EL4 cells. H-2 bib mice were (C57BL/10  x  A.BY)F~.  Values 
presented are percent CMC -  SE of the mean. 0.050 ml of a one:five serum dilution was added to 
each well. The final well volume was 0.175 ml and contained 2 ×  10  e spleen cells plus i  ×  104 '~Cr- 
labeled A13 target cells. 
§ P  value <0.01 compared to the same attackers in the presence of normal mouse serum. 
only on B lymphocytes, and spleen cells killed by this serum in the presence of 
C' can be assumed to be B cells (20). Anti-0 serum, on the other hand, kills only 
T lymphocytes. As shown in Table IV, exposure of attacker spleen cells to anti-0 
serum plus C' consistently abolished all CMC activity, whereas anti-Ia8 plus C' 
or normal mouse serum plus C' had no effect on CMC. This strongly implies that 
T lymphocytes are necessary for the CMC observed, and that B lymphocytes are 
not necessary. 
Adherent cells or macrophages have been implicated in tumor immunity (24). 
To  see if these  cells  were  necessary for  lysis  in  this  system,  glass-adherent 
spleen cells were removed from attacker populations, and the nonadherent cells 
were tested in the  CMC assay.  The results  (Table V) show that  nonadherent 
cells are equal to unfractionated populations in CMC activity. 
The  duration  of incubation  may be a  critical  factor influencing  the  results 
obtained  in  different  CMC  assay  systems.  Short  (3-6  h)  51Cr release  assays 
detect only the original effector population in the organ tested, whereas longer 
(24-48 h) microcytotoxicity assays allow in vitro proliferation  and differentia- 
tion of effector cells to occur (5, 25). Different results have been obtained in the 
MSV system using these two assays (26). Since the incubation period of our CMC 
assay was of intermediate duration (19 h), we decided to determine the contribu- 
tion of cell division by the attacker population to the CMC activity observed. 
The  effect of 2,000  R  irradiation  of attacker  spleen  cells  was  studied.  This 
amount  of irradiation  inhibits  cell division  without  killing  cells.  As  seen in 
Table  V,  this  treatment  lowered  the  CMC  activity,  but  did  not  abolish  it 
completely. The results imply that there are effector cells present in the attacker 
spleens at the time the spleen is removed, however, some additional mitosis in 
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TABLE  IV 
CMC Activity after Treatment of Attacker Spleen Cells with 
Anti-~ or A nti-Ia8 Serum Plus Complement 
Experiment 
Treatment of  attacker spleen cells 
NMS*  + C'  Anti-6 + C'  Anti-Ia8 + C' 
1  30.2  ±  0.8¢  -0.6  ±  0.1  29.3  -  1.0 
2  17.4  ±  0,4  -0.9  ±  0.5  15.6  ±  0.6 
3  10.0  ±  1.0  -0.4  ±  0.8  8.6  ±  1.4 
4  37.9  ±  1,5  1.0  ±  0.3  NT§ 
5  27.2  ±  0.4  1.2  ±  0.4  NT 
* Normal mouse serum. 
$ Values presented are percent CMC  ±  SE of the mean obtained in a 
CMC assay using A13 target cells and (C57BL/10  ×  A.BY)F1 anti-FV 
attacker spleen cells. 
§ NT, not tested. 
Discussion 
Spontaneous recovery from FV-induced leukemia has been shown to be influ- 
enced by many variables including virus strain  (27),  initial  virus dose (9,  11), 
and several host genes (8-11). The present experiments provide evidence for the 
presence of specific cytotoxic effector cells  in the  spleens of mice during  and 
shortly after recovery from FV-induced splenomegaly. Mice of beth Rfv-l~lb (high 
recovery incidence) and Rfv-ldlb (low recovery incidence) genotypes were able to 
produce effector cells in association with recovery from splenomegaly. Therefore 
this gene does not appear to function via an absolute control over production of 
these cells.  Among mice of either  genotype who had  recently recovered from 
splenomegaly, over 85% were positive in the CMC assay; only 2 of 26 mice with 
significantly enlarged  spleens were positive.  In all strains  tested there was a 
very strong statistical correlation between presence of specific cytotoxic effector 
cells  in  the  spleen  and  recent  recovery  from  splenomegaly.  Data  from  the 
previous paper indicated that no such correlation existed between presence of 
specific cytotoxic antibody and recovery from splenomegaly in these same mouse 
strains  (12).  The  available  evidence supports the hypothesis that the effector 
cells detected in  the  in  vitro  CMC  assay may play an  important  role in  the 
process of recovery from splenomegaly in vivo. 
It was consistently observed that spleen cells from some individual mice who 
had apparently recovered from splenomegaly did not produce in vitro lysis of 
A13 target cells. It is possible that this could be due to the inhibition of the CMC 
assay system by residual leukemia cells present in these spleens. This could also 
explain our failure  to see a  transient  peak of CMC activity in the spleens of 
progressor animals  as has been found in the  MSV system (28,  29).  Although 
spleen palpation has proven to be a relatively accurate measure of recovery from 
splenomegaly when weekly examinations  are made over the course of several 
months,  a  single palpation is a  crude index of disease state at any given time, 
and the presence of a  small  population of persistent  leukemia cells would be 
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TABLE V 
Effects of  Removal of Glass Adherent Cells or2,000 R Irradiation 
on Attacker Spleen Cell Populations 
Experiment 
Treatment  of  attacker  spleen  cells 
Glass  adherent  None  cells  removed 
2,000 R 
1  24.6  ±  0.8  22.2  +- 0.2 
2  15.4  ±  0.6  15.1  ±  0.5 
3  26.3  ±  1.3  20.4  ±  1.2 
4  38.2  ±  1.5  NT 
5  22.1  ±  0.6  NT 
6  60.5  ±  1.3  NT 
NT* 
NT 
NT 
9.4  ±  0.9 
12.1  ±  1.0 
26.9  ±  1.7 
*  Values  presented  are  percent  CMC ± 
CMC assay  using  A13 target  cells  and 
attacker  spleen  cells. 
*  NT, not  tested. 
SE of the mean obtained in a 
(C57BL/10 x A.BY)F1 anti-FV 
Inhibition CMC  tests  with normal spleen cells,  FV infected  spleen coils,  and 
FV itself  indicated  the specificity  of  immune lysis  of  A13 target cells  was for  FV- 
induced cellular  antigens. However, examination of a series of leukemia cell 
lines  as inhibitors  or  targets in  the  CMC  assay suggested that  the viral-induced 
cell membrane  antigens detected in CMC  were different  from the antigens 
detected by techniques using humoral antibodies.  Leukemia lines  of  H-2  orb and 
H-2  ~a types,  induced  by FV, Moloney leukemia virus,  Rauscher leukemia virus, 
and Bfr-L virus,  all  reacted  with antibodies from mice that  had recovered from 
FV leukemia. However, among these serologically  positive  cell  lines,  only those 
containing  H-2  b antigens were positive  in the CMC  assay using virus immune 
attackers.  One chemically-induced  H-2  blb leukemia (EL4) did not react  in  either 
the antibody or  cell-mediated virus-specific  assays. All cell  lines  listed  in Table 
II could be lysed by allogeneic attacker cells  immunized to the  H-2 specificities 
present on the  particular leukemia cell  line.  BC1 was the only  H-2  aid  cell  line  to 
show any sign of cell-mediated lysis  by anti-FV attacker cells.  This line was 
negative in the inhibition of lysis  of A13 cells;  however, in some assays with 
certain highly reactive H-2 btb attacker cells a low level of significant direct CMC 
was observed. Since it has previously been shown with LCM virus that virus- 
specific lysis of infected target cells by immune  lymphocytes requires partial 
identity between target and attacker cells at the H-2 locus (21), we also tested all 
our leukemia lines in CMC using immune attacker cells from H-2 atb mice, which 
have d  allele specificities in the D  region of the H-2  complex.  These attacker 
cells lysed the virus-antigen-positive  H.2 bib cells,  but failed to lyse the H-2 did 
cells. This observation would appear to rule out the possibility that the lack of vi- 
rus-specific lysis of  H-2 d~d cell lines was due to a requirement for partial identity 
at H-2 similar to that reportedfor the LCM virus system. However, recent data 
by Shearer  et al.  (30)  indicate  that  the  requirement  for H-2  identity  may be 
restricted to a specific region of the H-2 complex. Identity for the H-2D region in 
the case of H-2 atb attackers and H-2  aid targets may not be sufficient for lysis on 96  CELL-MEDIATED  IMMUNITY  AND  RECOVERY  FROM  LEUKEMIA 
this basis.  (B10.D2  ×  A.BY)FI  (H-2 dlb) attacker cells will have to be tested to 
completely rule out this possibility. 
One unexpected finding  could possibly indicate  that  a  requirement  for H-2 
identity may operate to some extent in the FV system. H-2 a~a  anti-FV  spleen 
cells were able to lyse only line 58 target cells (H-2b/h-35g),  which have H-2K  re- 
gion specificities identical withH-2 ~ (Table II). In contrast, H-2 bib cell lines, which 
were lysed by  H-2 bl~ and H-2 alb attackers, were not lysed by  H-2 al~ attacker cells. 
Due  to  rarity  of regression  of splenomegaly  in  H-2 ~  mice,  H-2 ~  anti-FV 
attacker spleen cells have not been studied by inhibition with normal and FV 
leukemic spleen cells to determine whether their lysis of line 58 cells is specific 
for virus-induced  cell  surface  antigens.  It  is theoretically  possible that  some 
nonviral related antigens are involved in this lysis. 
On the other hand, one additional piece of data should be stressed concerning 
the  possible  role  of an  H-2  identity  requirement  in  our  system.  H-2 ~  FV 
leukemic spleen cells were able to inhibit lysis of H-2 bib anti-FV attacker cells 
(Fig.  3).  In this  situation,  the  inhibitor  leukemia  cells shared  no partial  H-2 
identity  with  either  targets  or  attackers,  and  the  inhibition  appeared  to  be 
specific for virus-induced cell surface antigens only. A  similar result has been 
obtained using immunization in vitro with trinitrophenyl (TNP)-modified autol- 
ogous spleen cells (30). In some cases, lysis was independent of H-2 compatibili- 
ties and appeared to be hapten-specific only. 
The results of CMC inhibition experiments using various sera may be perti- 
nent  to  understanding  of the  specificities  toward which  the  CMC  activity is 
directed. H-2 d~ spleen cells immunized against virus-negative H-2 b~b EIA leuke- 
mia cells can lyse beth EL4 and A13 target cells. The major antigens recognized 
are H-2 b specificities, and the lysis can be inhibited by anti-H-2 b serum produced 
in H-2 d/d mice. This confirms the observation that antibodies to the appropriate 
determinants  can inhibit  CMC in a  51Cr release assay (22,  23).  Our efforts to 
obtain a similar specific inhibition using immune serum and attacker cells from 
mice, after recovery from FV leukemia, were unsuccessful. The explanations for 
both the lack of inhibition of virus-specific CMC by anti-FV sera and the lack of 
lysis  of virus  antigen-positive  H-2 d/~  leukemia  cells  are  unclear.  Our  data 
support the  idea that  the  specificities detected by CMC  and  antibody and  C' 
cytotoxicity are not identical.  A  similar conclusion was reached by two groups 
using  the  MSV system (28,  31).  Herberman  et al.  (31) hypothesized that  the 
antigens  detected in CMC after injection of MSV into C57BL/6 mice could be 
related to expression of an endogenous C-type virus, rather than to exogenous 
murine sarcoma virus. Alternatively, it is possible that the antigens detected in 
CMC are in fact directly induced by the exogenous murine viruses. The varia- 
tion  observed in the  cell-mediated  lysis of various  leukemia  target  cell  lines 
could  merely be  a  reflection  of quantitative  differences  of expression  of the 
pertinent cell surface antigens. 
Several  different effector mechanisms  of lysis could be ongoing simultane- 
ously when unfractionated spleen cells are mixed with tumor target cells (5-7). 
Using specific antisera capable of selectively killing T or B spleen lymphocytes 
we  investigated  the  nature  of the  effector  cells  demonstrated  in  this  CMC 
system. The results indicated that the effectors are T lymphocytes, as all CMC 
activity was abolished when these cells were killed.  Using anti-Ia8 serum and BRUCE  CHESEBRO  AND  KATHY  WEHRLY  97 
complement to kill the B  lymphocytes in the attacker spleen population had 
absolutely no  effect on  the  CMC  observed.  ADNCC,  a  mechanism of lysis 
believed to be mediated by non-T lymphocytes (5), was not seen in this system 
using anti-FV  serum  and  normal  spleen  cells,  whereas  ADNCC  was  easily 
demonstrated with an anti-H-2  h serum of equal titer. In addition, removal of 
glass-adherent cells from the spleen population did not abolish or reduce the 
CMC activity observed.  All these experiments indicate that the effector cells 
from anti-FV spleens are T lymphocytes which function in vitro without assist- 
ance or inhibition by B lymphocytes or macrophages. 
In  tumor immunology most authors,  including ourselves,  rely heavily on 
correlation of in vitro findings with in vivo observations. However, such results 
must be confirmed by more direct experimentation involving in vivo transfer of 
fractionated effector cell populations, antibodies, or inhibitory factors to tumor- 
bearing animals. This has been carried out to some extent in the MSV system, 
and the results suggest T lymphocytes are effective against tumor challenge in 
vivo  (32, 33). In  another  laboratory,  passive  transfer of antiserum has  also 
proven  effective against tumor challenge  (34). However,  passive  transfer of 
serum or cells before or just after tumor challenge may not be equivalent to 
rejection of an established tumor. In the case of FV leukemia, passively trans- 
ferred antiserum is effective against small numbers of  early (1-3 day) FV spleen 
colonies, whereas such antibody appears to have little effect on the recovery 
from leukemic splenomegaly which can be seen in this system (12). 
The role of nonspecific systemic or local effector mechanisms in recovery from 
FV  leukemia has  not  been  examined in  this  study.  It  is  evident that such 
mechanisms play an important role in control of virus infection (35) and tumor 
growth (36, 37) in other systems, and most certainly are a significant factor in 
murine leukemia as well (38). Understanding the complex interactions and host 
genetic controls of  these mechanisms should be a major goal in the field of tumor 
biology. 
Summary 
Congenic mouse strains differing only at genes within the H-2 complex were 
found to have virus-specific cytotoxic effector cells in their spleens during or 
after recovery from Friend leukemia virus-induced splenomegaly. These effector 
cells were 0-positive T lymphocytes which functioned in vitro without help or in- 
hibition by B  lymphocytes or glass-adherent cells.  The antigenic specificities 
recognized by the effector cells were viral-induced cellular antigens apparently 
different from those identified by serological techniques. 
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